At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Nov 4, 2026 at 16:01 ET
Dianthus Therapeutics reported Q3 2026 net loss of $46.6M ($0.81 per share), wider than the $36.8M loss in Q3 2025, but the EPS of -$0.81 beat the consensus estimate of -$0.95. The company highlighted strong clinical progress across its pipeline, including a 75% response rate in the CIDP Phase 3 CAPTIVATE trial interim analysis and a $1.2B cash runway into 2030.
- Q3 2026 net loss of $46.6M ($0.81 per share) vs $36.8M ($0.97 per share) in Q3 2025
- EPS of -$0.81 beat consensus estimate of -$0.95
- Revenue of $1.21M (license revenue) vs $396K in Q3 2025, well above $389K consensus
- Cash, cash equivalents and investments of ~$1.2B as of Sep 30, 2026, providing runway into 2030
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access